9 September 2024
Norman Broadbent
plc
("Norman
Broadbent", the "Company" or the "Group")
Interim results for the six
months ended 30 June 2024
Norman Broadbent (AIM: NBB), a leading Executive Search and
Interim Management firm,
is pleased to announce its unaudited interim
results for the six months ended 30 June 2024 ("H1 2024").
Financial
Highlights
·
|
Revenue of £5.0m, down 18% (H1 2023:
£6.1m)
|
·
|
Net fee income ("NFI") of £4.5m, down 13% on an
exceptional H1 2023 (H1 2023: £5.2m) and up 36% on H1 2022 (H1
2022: £3.3m)
|
·
|
Underlying1 EBITDA of
£0.13m, £0.1m bad debt provision (H1 2023: £0.27m)
|
·
|
Net debt (excluding lease
liabilities) of £0.7m, a 42% improvement (H1 2023: net debt
£1.2m)
|
·
|
Net cash used in operations of
£1.0m; reflecting the timing of annual bonus payments which are
made to employees during the first half of the subsequent year and
acknowledging that fee-generation in FY 2023 was exceptionally
strong year-on-year ("YoY")
|
Operational
Highlights
·
|
20% growth in fee earner headcount
YoY, positioning the Company to capitalise on a recovery, with
additional hires taking place in H2 2024
|
·
|
Implementation of improved
technology platforms including integration of Microsoft Power BI to
enhance data visualisation, reporting capabilities and
decision-making processes
|
·
|
Awarded a Two Star
accreditation by employee engagement specialist Best Companies
for an 'outstanding' level of workplace engagement
|
·
|
New head office lease secured in a
higher quality and more cost-effective building in the City of
London
|
[1] Underlying EBITDA excludes share based payment
charges
Kevin Davidson, CEO of Norman Broadbent,
said:
"The pressures across the recruitment sector have been
well-publicised, and growth has been made even more challenging
when compared with an exceptional H1 2023 for the Company. Despite
this, we continue to win and deliver good quality mandates, and
importantly, NFI is still up considerably compared to H1 2022.
Taking a longer-term view, the Company is in good health and we
remain focused on positioning the Company to capitalise on the
recovering market.
While we cannot influence market conditions, we can control
how we adapt to them. A key focus in the year to date has therefore
been to carefully manage overheads while continuing to make
progress by upgrading and developing our talent, enhancing our
systems and processes, and reinforcing the culture that underpins
the Company.
While the timing of a recovery remains hard to predict, there
are some positive signs beginning to emerge across the industry.
Our average monthly retainer income in Q3 2024 is already slightly
up on both Q1 and Q2 2024, in line with reports that the
contraction of the labour market is easing. With the action we are
taking to build on the positive transformation activity of recent
years, we are in good shape to emerge strongly and quickly once
conditions improve."
Copies of this announcement are
available on the Company's website, at www.normanbroadbent.com
Investor Presentation:
CEO Kevin Davidson and CFO Mehr
Malik will host a virtual presentation and
Q&A session open to all existing and potential shareholders at
11am this morning. To register to attend, please use the following
link: https://bit.ly/NBB_H124_results_webinar
Contacts:
Norman Broadbent
plc
|
+44 (0)20 7484 0000
|
Kevin Davidson, CEO
|
|
Mehr Malik, CFO
|
|
Shore Capital (Nominated Adviser and
Broker)
|
+44 (0)20 7408 4090
|
Tom
Griffiths / Tom Knibbs (Corporate Advisory)
|
|
Henry Willcocks (Corporate
Broking)
|
|
Alma (Financial Communications
Adviser)
|
+44 (0)20
3405 0205
|
Rebecca Sanders-Hewett
|
normanbroadbent@almastrategic.com
|
Kinvara Verdon
|
|
David Ison
|
|
About Norman Broadbent:
Norman Broadbent (AIM: NBB) is a
professional services firm focused on executive search, senior
interim management solutions and bespoke leadership advisory
services working across the UK and internationally.
Established as the first
UK-headquartered search firm in 1979, the firm has a 40+ year track
record of shaping leadership across industries including Consumer,
Financial Services, Industrials, Life Sciences, Investor and
TMT.
www.normanbroadbent.com
CEO's
Statement
Norman Broadbent has delivered
growth in headcount, capability and capacity in H1 2024 whilst also
continuing to generate positive EBITDA. This has been achieved
amidst a challenging period for the recruitment sector and
positions Norman Broadbent for future growth when the market
recovers.
Additional and improved fee earners
New hires continue to establish
themselves and H1 2024 has seen us deepen our capabilities and
reach across key sectors and corporate functions, including
Industrial, Investor, Digital & Technology, Life Sciences,
Finance and Change & Transformation. Since the period end, the
Company has already secured additional fee earners to bolster and
expand our footprint in Renewable Energy, Clean Technology and
Civil Aviation. There are other fee generating hires in process
both in the UK and the US and we remain disciplined in terms of
quality and cultural alignment on all prospective
recruits.
Expanded our practices and gathered momentum
Whilst building out our capabilities
across our established verticals such as Industrials (including
chemicals, aerospace and aviation, energy, power, utilities,
automotive and mining), Retail & Consumer and Technology, we
re-established other practices in areas where the Company
historically operated and the brand remains strong such as Board,
Investor and Life Sciences. Each of these presents considerable
growth opportunities and has been gathering momentum.
Successful international expansion
In H1 2024, the Company worked on
projects across the UK and Europe, the US, Asia and the Middle
East. It has purposefully developed its international client base
and brand over the past two years, and it is very pleasing to see
that 29% of H1 2024's NFI was generated from international
assignments (H1 2023: 24%). This international spread of business
enables the Company to capitalise fully on global key accounts,
secure the most senior mandates, mitigate risk and open multiple
fronts for continued growth.
Reinforced our culture and brand
We continue to focus on culture as
the bedrock of the Company, recognising that the attraction,
retention, motivation and development of talent is the driver for
growth and value creation. Being shortlisted at the Small Cap
Network Awards for our work around ED&I and being recognised as
outstanding in terms of employee engagement by Best Companies are
both testament to our commitment to one
another.
Enhanced systems, processes and premises
As part of our efforts to strengthen
the Company during the period, we enhanced our productivity through
the implementation of improved technology, including the
integration of Microsoft Power BI to enhance data
visualisation, reporting capabilities and decision-making
processes. We have also strengthened our client and candidate
feedback processes to ensure continuous improvement and greater
responsiveness to market needs.
We have secured a new head office
lease in a higher quality, and more cost effective, building in the
City of London which better reflects the evolution of Norman
Broadbent's brand and its growth ambitions.
The Board practice has conducted a
number of board effectiveness reviews this year along with placing
Chairs and other non-executive directors in blue chip companies
from AIM quoted mid-caps to public sector and privately owned
enterprises. Recommitting to this space clearly drives brand
penetration across key decision makers, providing much pull through
business opportunities across the Group.
The Investor practice works closely
with other verticals to ensure a collaborative approach to
developing and executing business. This team has secured work in
2024 in the UK and US, supporting investors (primarily VC and PE)
and their portfolios with leadership challenges across industrial,
consumer, life sciences and financial services. As relationships
expand and deepen across this sector and the economic landscape
recovers, the growth from this team could be
considerable.
We have successfully re-established
our Healthcare & Life Science Practice with three fee earners
in Manchester and Cambridge. Whilst this is a vast sector offering
considerable room for further expansion, we have already made great
progress on the manufacturing, generics, diagnostics and biotech
areas of the market. This team has already secured mandates in the
UK, Czechia, Germany, India, the US and the Kingdom of Saudi
Arabia.
Focused M&A strategy
Whilst maintaining our focus on
organic growth, the Company continues to actively identify and
explore synergistic acquisition opportunities.
Dividend
The Board does not declare the
payment of an interim dividend (2023: nil pence).
Summarised Financial Results:
The table below summarises the
financial results for the Group:
|
Six months ended 30 Jun
2024
|
Six months
ended 30 Jun 2023
|
Year ended
31 Dec 2023
|
|
£000's
(unaudited)
|
£000's
(unaudited)
|
£000's
(audited)
|
|
|
|
|
Revenue
|
5,042
|
6,057
|
12,306
|
Cost of sales
|
(565)
|
(879)
|
(1,731)
|
|
|
|
|
Gross profit (Net Fee Income)
|
4,477
|
5,178
|
10,575
|
Operating expenses
|
(4,348)
|
(4,907)
|
(9,679)
|
|
|
|
|
|
|
|
|
Underlying EBITDA1
|
129
|
271
|
896
|
Share based payment
charge
|
(83)
|
(82)
|
(253)
|
EBITDA
|
46
|
189
|
643
|
|
|
|
|
Depreciation and
amortisation
|
(102)
|
(111)
|
(231)
|
|
|
|
|
Group operating (loss)/profit before interest and
tax
|
(56)
|
78
|
412
|
Net finance cost
|
(17)
|
(70)
|
(103)
|
(Loss)/profit before tax
|
(73)
|
8
|
309
|
Income tax expense
|
-
|
-
|
-
|
(Loss)/profit after tax
|
(73)
|
8
|
309
|
Financial Position
As at 30 June 2024, equity
shareholders' funds were £1.4m (30 June 2023: £0.8m). Total
liabilities have reduced by £1.5m to £2.6m reflecting improvements
in working capital management with significantly less reliance on
financing facility and early redemption and conversion of
convertible loans during 2023 (30 June 2023: £4.1m).
Net debt (excluding lease
liabilities) improved to £0.7m YoY (30 June 2023: £1.2m).
Net cash used in operations of £1.0m, reflective
of the timing of annual bonus payments which are made to employees
during the first half of the subsequent year. The fee-generation in
FY 2023 was exceptionally strong, with bonus cash outflows during
H1 2024. Cash and cash equivalents at 30 June 2024
amounted to £48k (30 June 2023: £81k).
Outlook
While the market remains tough, as
reported in recent announcements by virtually all companies in our
sector, several industry indicators suggest a gradual stabilisation
is underway. We are seeing pockets of increased activity and are
encouraged by the gradually improving retainer income so far in Q3
2024. However, given the inherent quarter-to-quarter variability in
the Company and uncertainty around the pace of the broader
recovery, it is difficult to say with any certainty whether we are
back on a positive trajectory or if this is an isolated
uptick.
We continue to take steps to manage
the Company through the challenging conditions while maintaining
sufficient levels of investment to ensure that we capitalise on the
opportunities presented by the recovery and have the means to
continue to pursue our long-term growth ambitions. Crucially, we
have strengthened our fee earning talent considerably, both in
terms of quality and headcount, and have ambitious plans to
continue in the same vein in the second half and beyond. The Board
believes this is the right strategy to deliver sustainable and
profitable long-term growth.
Looking ahead, the new hires we have
made in H1 2024 and those anticipated in the second half coupled
with the hard work that has taken place behind the scenes to
strengthen our operations give us confidence that, assuming the
market improves as expected, we will meet our target of £1.25
million of EBITDA in 2025.
Kevin Davidson
Chief Executive
09 September 2024
CONSOLIDATED STATEMENT OF COMPREHENSIVE
INCOME
For
the six months ended 30 June 2024
|
Note
|
Six months
ended
|
|
Six months
ended
|
|
Year
ended
|
|
|
30 June
|
|
30
June
|
|
31
December
|
|
|
2024
|
|
2023
|
|
2023
|
|
|
(unaudited)
|
|
(unaudited)
|
|
(audited)
|
|
|
£000
|
|
£000
|
|
£000
|
|
|
|
|
|
|
|
Revenue
|
2
|
5,042
|
|
6,057
|
|
12,306
|
|
|
|
|
|
|
|
Cost of Sales
|
|
(565)
|
|
(879)
|
|
(1,731)
|
|
|
|
|
|
|
|
Gross profit (Net Fee Income)
|
|
4,477
|
|
5,178
|
|
10,575
|
Operating expenses
|
|
(4,533)
|
|
(5,100)
|
|
(10,163)
|
|
|
|
|
|
|
|
Operating (loss)/profit from continued
operations
|
|
(56)
|
|
78
|
|
412
|
Net finance cost
|
|
(17)
|
|
(70)
|
|
(103)
|
(Loss)/profit on ordinary activities before income
tax
|
|
(73)
|
|
8
|
|
309
|
|
|
|
|
|
|
|
Income tax expense
|
|
-
|
|
-
|
|
-
|
Total comprehensive (loss)/profit for the
period
|
|
(73)
|
|
8
|
|
309
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss)/profit per share
|
3
|
|
|
|
|
|
- Basic
|
|
(0.11p)
|
|
0.01p
|
|
0.50p
|
- Diluted
|
|
(0.11p)
|
|
0.01p
|
|
0.39p
|
|
|
|
|
|
|
|
Adjusted profit per share
|
|
|
|
|
|
|
- Basic
|
|
0.02p
|
|
0.14p
|
|
0.91p
|
- Diluted
|
|
0.00p
|
|
0.14p
|
|
0.71p
|
|
|
|
|
|
|
|
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As
at 30 June 2024
|
Note
|
As at
|
|
As
at
|
|
As
at
|
|
|
30 June
|
|
30
June
|
|
31
December
|
|
|
2024
|
|
2023
|
|
2023
|
|
|
(unaudited)
|
|
(unaudited)
|
|
(audited)
|
|
|
£000
|
|
£000
|
|
£000
|
Non-current assets
|
|
|
|
|
|
|
Intangible assets
|
|
1,363
|
|
1,363
|
|
1,363
|
Property, plant and
equipment
|
|
251
|
|
301
|
|
178
|
Total non-current assets
|
|
1,614
|
|
1,664
|
|
1,541
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
Trade and other
receivables
|
|
2,315
|
|
3,143
|
|
2,901
|
Cash and cash equivalents
|
|
48
|
|
81
|
|
765
|
Total current assets
|
|
2,363
|
|
3,224
|
|
3,666
|
|
|
|
|
|
|
|
Total assets
|
|
3,977
|
|
4,888
|
|
5,207
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
Trade and other payables
|
|
1,668
|
|
2,609
|
|
3,393
|
Bank Loans and Loan Note
|
4
|
633
|
|
1,140
|
|
207
|
Lease liabilities
|
|
117
|
|
237
|
|
111
|
Total current liabilities
|
|
2,418
|
|
3,986
|
|
3,711
|
|
|
|
|
|
|
|
Net
current assets/(liabilities)
|
|
(55)
|
|
(762)
|
|
(45)
|
|
|
|
|
|
|
|
Non
Current Liabilities
|
|
|
|
|
|
|
Lease liabilities
|
|
87
|
|
9
|
|
8
|
Bank Loan and Loan Note
|
4
|
87
|
|
133
|
|
113
|
|
|
174
|
|
142
|
|
121
|
|
|
|
|
|
|
|
Total liabilities
|
|
2,592
|
|
4,128
|
|
3,823
|
|
|
|
|
|
|
|
Total assets less total liabilities
|
|
1,385
|
|
760
|
|
1,375
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
Issued share capital
|
|
6,395
|
|
6,345
|
|
6,365
|
Own shares reserve
|
|
(30)
|
|
-
|
|
-
|
Share premium account
|
|
14,233
|
|
14,110
|
|
14,233
|
Retained earnings
|
|
(19,213)
|
|
(19,695)
|
|
(19,223)
|
|
|
|
|
|
|
|
Total equity
|
|
1,385
|
|
760
|
|
1,375
|
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For
the six months ended 30 June 2024
|
Share
Capital
|
Share
Premium
|
Shares held by
EBT
|
Retained
Earnings
|
Total
Equity
|
|
£000
|
£000
|
£000
|
£000
|
£000
|
|
|
|
|
|
|
Balance at 1 January 2023
|
6,345
|
14,110
|
0
|
(19,785)
|
670
|
Profit for the period
|
-
|
-
|
-
|
8
|
8
|
Total comprehensive profit for the period
|
-
|
-
|
-
|
8
|
8
|
Credit to equity for share based
payments
|
-
|
-
|
-
|
82
|
82
|
Balance at 30 June 2023 (unaudited)
|
6,345
|
14,110
|
-
|
(19,695)
|
760
|
|
|
|
|
|
|
Balance at 1 July 2023
|
6,345
|
14,110
|
-
|
(19,695)
|
760
|
Profit for the period
|
-
|
-
|
-
|
301
|
301
|
Total other comprehensive
income
|
-
|
-
|
-
|
-
|
-
|
Total comprehensive profit for the period
|
-
|
-
|
-
|
301
|
301
|
|
|
|
|
|
|
Credit to equity for share based
payments
|
-
|
-
|
-
|
171
|
171
|
Conversion of convertible loan
notes
|
20
|
123
|
-
|
-
|
143
|
Total transactions with owners of the
Company
|
20
|
123
|
-
|
171
|
314
|
Balance at 31 December 2023 (audited)
|
6,365
|
14,233
|
-
|
(19,223)
|
1,375
|
|
|
|
|
|
|
Balance at 1 January 2024
|
6,365
|
14,233
|
-
|
(19,223)
|
1,375
|
Loss for the period
|
-
|
-
|
-
|
(73)
|
(73)
|
Total comprehensive loss for the period
|
-
|
-
|
-
|
(73)
|
(73)
|
Issue of shares
|
30
|
-
|
-
|
-
|
30
|
Shares acquired by the
EBT
|
-
|
-
|
(30)
|
-
|
(30)
|
Credit to equity for share based
payments
|
-
|
-
|
-
|
83
|
83
|
Balance at 30 June 2024 (unaudited)
|
6,395
|
14,233
|
(30)
|
(19,213)
|
1,385
|
CONSOLIDATED STATEMENT OF CASH FLOW
For the six months ended 30 June 2024
|
Note
|
Six months ended 30 June 2024
(unaudited)
|
|
Six months
ended 30 June 2023 (unaudited)
|
|
Year
ended
31
December 2023
(audited)
|
|
|
£000
|
|
£000
|
|
£000
|
|
|
|
|
|
|
|
Net
cash generated by / (used in) operating
activities
|
(i)
|
(1,010)
|
|
52
|
|
1,712
|
|
|
|
|
|
|
|
Cash flows from investing activities and servicing of
finance
|
|
|
|
|
|
|
Net finance cost
|
|
(7)
|
|
(18)
|
|
(27)
|
Payments to acquire tangible fixed
assets
|
|
(28)
|
|
(11)
|
|
(16)
|
Net
cash generated by / (used in) investing
activities
|
|
(35)
|
|
(29)
|
|
(43)
|
|
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
Repayment of borrowings
|
|
(31)
|
|
(257)
|
|
(389)
|
Increase / (decrease) in invoice
discounting
|
|
423
|
|
386
|
|
(324)
|
Payment of finance lease
liabilities
|
|
(64)
|
|
(121)
|
|
(241)
|
|
|
|
|
|
|
|
Net
cash from financing activities
|
|
328
|
|
8
|
|
(954)
|
|
|
|
|
|
|
|
Net
(decrease)/ increase in cash and cash equivalents
|
|
(717)
|
|
31
|
|
715
|
Net
cash and cash equivalents at beginning of period
|
|
765
|
|
50
|
|
50
|
Net
cash and cash equivalents at end of period
|
48
|
|
81
|
|
765
|
|
|
|
|
|
|
|
Analysis of net funds (pre lease
liabilities)
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
48
|
|
81
|
|
765
|
Borrowings due within one
year
|
|
(633)
|
|
(1,140)
|
|
(207)
|
Borrowings due within more than one
year
|
|
(87)
|
|
(133)
|
|
(113)
|
|
|
|
|
|
|
|
Net
(debt)/ funds
|
|
(672)
|
|
(1,192)
|
|
445
|
|
|
|
|
|
|
|
Note (i)
|
|
|
|
|
|
|
Reconciliation of operating profit to net cash from operating
activities
|
|
Six months ended 30 June 2024
(unaudited)
|
|
Six months
ended 30 June 2023 (unaudited)
|
|
Year ended 31 December
2023
(audited)
|
Operating profit / (loss) from
continued operations
|
|
(56)
|
|
78
|
|
412
|
Depreciation of property, plant and
equipment
|
|
102
|
|
111
|
|
231
|
Share based payment
charge
|
|
83
|
|
82
|
|
253
|
(Increase)/decrease in trade and
other receivables
|
|
586
|
|
(823)
|
|
(579)
|
Increase/(decrease) in trade and
other payables
|
|
(1,725)
|
|
604
|
|
1,395
|
Net
cash generated by / (used in) operating
activities
|
|
(1,010)
|
|
52
|
|
1,712
|
|
|
|
|
|
|
|
NOTES TO THE FINANCIAL STATEMENTS
1.
ACCOUNTING POLICIES
1.1 Basis of
preparation
The financial information set out in
these interim financial statements does not constitute statutory
accounts as defined in Section 435 of the Companies Act 2006. The
Group's statutory financial statements for the year ended 31
December 2023, prepared under International Financial Reporting
Standards (IFRS), have been filed with the Registrar of Companies.
The auditor's report on those statements was
unqualified.
The interim financial information
for the six months ended 30 June 2024, has been prepared in
accordance with the AIM Rules for Companies. The Group has not
elected to apply IAS 34 'Interim Financial Reporting'. The
principal accounting policies used in preparing the interim results
are those the Group expects to apply in its financial statements
for the year ending 31 December 2024 and are unchanged from those
disclosed in the Group's Annual Report for the year ended 31
December 2023. The interim financial statements have not been
audited.
1.2 Basis of
consolidation and business combinations
Group financial statements
consolidate those of the Company and of the following subsidiary
undertakings:
Principal Group investments:
|
|
Country of incorporation or registration and
operation
|
Principal activities
|
Description and proportion of shares held by the
Company
|
|
|
|
|
|
Norman Broadbent Executive Search
Ltd
|
|
England and Wales
|
Executive Search
|
100 per cent ordinary
shares
|
Norman Broadbent (Ireland)
Ltd
|
|
Republic of Ireland
|
Dormant
|
100 per cent ordinary
shares
|
|
|
|
|
|
2.
SEGMENTAL ANALYSIS
Group revenues are primarily driven
from UK operations. However, when revenue is derived from overseas
business, the results are presented to the Board by geographic
region to identify potential areas for growth or those posing
potential risks to the Group.
i)
Revenue by class of business:
|
Revenue
£'000
|
|
Six Months
Ended
|
Six Months
Ended
|
Year
Ended
|
|
30 June
|
30
June
|
31
December
|
|
2024
|
2023
|
2023
|
|
(unaudited)
|
(unaudited)
|
(audited)
|
Search
|
3,897
|
4,048
|
8,585
|
Interim Management
|
1,061
|
1,776
|
3,189
|
Leadership consulting
|
67
|
219
|
501
|
Other
|
17
|
14
|
31
|
Total
|
5,042
|
6,057
|
12,306
|
ii) Revenue by
geography:
|
Revenue
£'000
|
|
Six Months
Ended
|
Six Months
Ended
|
Year
Ended
|
|
30 June
|
30
June
|
31
December
|
|
2024
|
2023
|
2023
|
|
(unaudited)
|
(unaudited)
|
(audited)
|
United Kingdom
|
3,930
|
4,513
|
9,078
|
Rest of World
|
1,112
|
1,544
|
3,228
|
Total
|
5,042
|
6,057
|
12,306
|
3.
(LOSs)/Profit PER ORDINARY SHARE
i) Basic
(loss)/profit per share:
This is calculated by dividing the (loss)/profit attributable to
equity holders of the Company by the weighted average number of
ordinary shares in issue during the period:
|
Six Months
Ended
|
Year
Ended
|
|
30 June
|
30
June
|
31
December
|
|
2024
|
2023
|
2023
|
|
(unaudited)
|
(unaudited)
|
(audited)
|
|
|
|
|
(Loss)/profit attributable to
shareholders (£'000)
|
(73)
|
8
|
309
|
Weighted average number of ordinary
share (000's)
|
63,865
|
61,818
|
62,104
|
ii)
Diluted (loss)/profit per share:
This is calculated
by adjusting the weighted average number of
ordinary shares outstanding to assume conversion of all potentially
dilutive issues of ordinary shares. The Company has issued share
options which are potentially dilutive. A calculation is done to
determine the number of shares that could have been acquired at
fair value (determined as the average annual price of the Company's
shares) based on the monetary value of the subscription rights
attached to the outstanding options. The number of shares
calculated as above is compared with the number of shares that
would have been issued assuming the exercise of the share
options.
|
|
Six months ended 30 June
2024
|
Six months
ended 30 June 2023
|
Year ended
31 December 2023
|
|
|
(unaudited)
|
(unaudited)
|
(audited)
|
|
|
|
|
|
(Loss)/profit attributable to
shareholders (£'000)
|
|
(73)
|
8
|
309
|
|
|
|
|
|
Weighted average no. of ordinary
shares (000's)
|
|
63,865
|
61,818
|
62,104
|
|
|
|
|
|
Weighted average number of ordinary
shares for diluted earnings per share
|
|
79,901
|
61,818
|
78,464
|
iii) Adjusted
(loss)/profit per share
Adjusted (loss)/profit per share has
also been calculated in addition to the basic and diluted loss per
share and is based on losses adjusted to eliminate charges for
share based payments. It has been calculated to allow shareholders
to gain a clearer understanding of the trading performance of the
Group.
|
Six months ended 30 June
2024
|
Six
months ended 30 June 2023
|
Year
ended 31 December 2023
|
|
(unaudited)
|
(unaudited)
|
(audited)
|
|
|
Basic
|
Diluted
|
|
Basic
|
Diluted
|
|
Basic
|
Diluted
|
|
|
pence per
|
pence per
|
|
pence
per
|
pence
per
|
|
pence
per
|
pence
per
|
|
|
share
|
share
|
|
share
|
share
|
|
share
|
share
|
|
£'000
|
|
|
£'000
|
|
|
£'000
|
|
|
Basic earnings
|
|
|
|
|
|
|
|
|
|
Profit/(loss) after tax
|
(73)
|
(0.11)
|
(0.09)
|
8
|
0.01
|
0.01
|
309
|
0.50
|
0.39
|
Adjustment
|
|
|
|
|
|
|
|
|
|
Share based payment
charge
|
83
|
0.13
|
0.11
|
82
|
0.13
|
0.13
|
253
|
0.41
|
0.32
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
|
10
|
0.02
|
0.00
|
90
|
0.14
|
0.14
|
562
|
0.91
|
0.71
|
|
|
|
|
|
|
|
|
|
|
4. BORROWINGS
|
Six months
ended
|
Six months
ended
|
Year
ended
|
|
30 June
|
30
June
|
31
December
|
|
2024
|
2023
|
2023
|
|
(unaudited)
|
(unaudited)
|
(audited)
|
|
£'000
|
£'000
|
£'000
|
|
|
|
|
Invoice discounting facility (see
note (a) below)
|
582
|
869
|
159
|
Loans (see note (b)
below)
|
138
|
404
|
161
|
|
|
|
|
Total
|
720
|
1,273
|
320
|
(a) Invoice discounting facility
The Group operates an invoice
discounting facility with Metro Bank. All Group invoices are
raised through Norman Broadbent Executive Search Limited and as
such Metrobank (SME Invoice Finance Limited) holds an all asset
debenture for Norman Broadbent plc and Norman Broadbent Executive
Search Limited. At as 30 June 2024, the outstanding balance
on the facility of £0.6m was secured by trade receivables of
£2.1m. Interest is charged on the drawn down funds at a rate
of 2.4% above the bank base rate.
(b) Loans
In November 2020, the Group received
a CBILS loan of £250,000 for a term of 6 years. Repayment of
capital and interest began in January 2023, and the loan incurs
interest at 4.75% above the Metro Bank UK base rate. Metro Bank
holds an all asset fixed and floating charge over Norman Broadbent
Executive Search Limited linked to this facility.
During 2023, Convertible Loan Notes
(CLNs) to Downing Strategic Micro-Cap Investment Trust Plc and
Moulton Goodies Limited for £200,000 each were fully redeemed and
repaid. £200,000 of the CLNs plus interest was repaid in May
2023. During November 2023, £100,000 of the CLNs was repaid and the
Company allotted 2,047,706 new ordinary shares of 1p each at a
conversion price of 7.0 pence per share for the remaining £100,000
of CLNs plus repayment of all interest due and the redemption
fee.